<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Melatonin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01065</strong>&#160; (APRD00742, DB08189)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, nutraceutical</td></tr><tr><th>Description</th><td><p>Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958.  In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus) but outside the blood-brain barrier. The secretion of melatonin increases in darkness and decreases during exposure to light, thereby regulating the circadian rhythms of several biological functions, including the sleep-wake cycle. In particular, melatonin regulates the sleep-wake cycle by chemically causing drowsiness and lowering the body temperature.  Melatonin is also implicated in the regulation of mood, learning and memory, immune activity, dreaming, fertility and reproduction. Melatonin is also an effective antioxidant.  Most of the actions of melatonin are mediated through the binding and activation of melatonin receptors. Individuals with autism spectrum disorders (<span class="caps">ASD</span>) may have lower than normal levels of melatonin. A 2008 study found that unaffected parents of individuals with <span class="caps">ASD</span> also have lower melatonin levels, and that the deficits were associated with low activity of the <span class="caps">ASMT</span> gene, which encodes the last enzyme of melatonin synthesis. Reduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01065/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01065/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01065.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01065.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01065.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01065.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01065.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01065">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>5-methoxy-N-acetyltryptamine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>N-[2-(5-methoxyindol-3-yl)ethyl]acetamide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>N-Acetyl-5-methoxytryptamine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Circadin</td><td>Lundbeck (France, United Kingdom), Neurim Pharmaceutical Labs (Israel, Denmark, Greece, Norway, Poland, Portugal), Nycomed (Belgium, Sweden)</td></tr><tr><td>Mela-T</td><td>Alacer Corp. (Canada)</td></tr><tr><td>Melatol</td><td>Elisium (Argentina)</td></tr><tr><td>Melatonin</td><td>Biomed International Products Corp., Nutravite Pharmaceuticals (2008) Inc., Viva Pharmaceutical Inc., Kripps Pharmacy Ltd., SunOpta Inc.</td></tr><tr><td>Nature'S Harmony</td><td>SunOpta Inc. (Canada)</td></tr><tr><td>Revital Melatonin</td><td>Chin Tai Ginseng Co., Ltd (Canada)</td></tr><tr><td>Rx Balance</td><td>SunOpta Inc. (Canada)</td></tr><tr><td>Sleep Right</td><td>SunOpta Inc. (Canada)</td></tr><tr><td>Vivitas</td><td>SunOpta Inc. (Canada)</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Plenovit Melatonina</td><td>melatonin + vitamin B6</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antioxidants">Antioxidants</a></li>
<li><a href="/mesh/central-nervous-system-depressants">Central Nervous System Depressants</a></li></ul></td></tr><tr><th>CAS number</th><td>73-31-4</td></tr><tr><th>Weight</th><td>Average: 232.2783<br>Monoisotopic: 232.121177766</td></tr><tr><th>Chemical Formula</th><td>C<sub>13</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub></td></tr><tr><th>InChI Key</th><td>DRLFMBDRBRZALE-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C13H16N2O2/c1-9(16)14-6-5-10-8-15-13-4-3-11(17-2)7-12(10)13/h3-4,7-8,15H,5-6H2,1-2H3,(H,14,16)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">N-[2-(5-methoxy-1H-indol-3-yl)ethyl]acetamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">COC1=CC2=C(NC=C2CCNC(C)=O)C=C1</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB01065.gif?1265922774">show</a>(8.2 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Indoles and Derivatives</td></tr><tr><th>Subclass</th><td>Tryptamines and Derivatives</td></tr><tr><th>Direct parent</th><td>Serotonins</td></tr><tr><th>Alternative parents</th><td>Indoles; Anisoles; Alkyl Aryl Ethers; Substituted Pyrroles; Secondary Carboxylic Acid Amides; Carboxylic Acids; Enolates; Polyamines</td></tr><tr><th>Substituents</th><td>indole; anisole; phenol ether; alkyl aryl ether; benzene; substituted pyrrole; pyrrole; secondary carboxylic acid amide; carboxamide group; ether; carboxylic acid; polyamine; enolate; carboxylic acid derivative; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the serotonins. These are compounds containing a serotonin moiety, which conists of an indole that bears an aminoethyl a position 2 and an hydroxyl group at position 5.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Used orally for jet lag, insomnia, shift-work disorder, circadian rhythm disorders in the blind (evidence for efficacy), and benzodiazepine and nicotine withdrawal. Evidence indicates that melatonin is likely effective for treating circadian rhythm sleep disorders in blind children and adults. It has received FDA orphan drug status as an oral medication for this use. A number of studies have shown that melatonin may be effective for treating sleep-wake cycle disturbances in children and adolescents with mental retardation, autism, and other central nervous system disorders. It appears to decrease the time to fall asleep in children with developmental disabilities, such as cerebral palsy, autism, and mental retardation. It may also improve secondary insomnia associated with various sleep-wake cycle disturbances. Other possible uses for which there is some evidence for include: benzodiazepine withdrawal, cluster headache, delayed sleep phase syndrome (DSPS), primary insomnia, jet lag, nicotine withdrawal, preoperative anxiety and sedation, prostate cancer, solid tumors (when combined with IL-2 therapy in certain cancers), sunburn prevention (topical use), tardive dyskinesia, thrombocytopenia associated with cancer, chemotherapy and other disorders. </td></tr><tr><th>Pharmacodynamics</th><td>Melatonin is a hormone normally produced in the pineal gland and released into the blood. The essential amino acid L-tryptophan is a precursor in the synthesis of melatonin. It helps regulate sleep-wake cycles or the circadian rhythm. Production of melatonin is stimulated by darkness and inhibited by light. High levels of melatonin induce sleep and so consumption of the drug can be used to combat insomnia and jet lag.
MT1 and MT2 receptors may be a target for the treatment of circadian and non circadian sleep disorders because of their differences in pharmacology and function within the SCN. SCN is responsible for maintaining the 24 hour cycle which regulates many different body functions ranging from sleep to immune functions
</td></tr><tr><th>Mechanism of action</th><td>Melatonin is a derivative of tryptophan. It binds to melatonin receptor type 1A, which then acts on adenylate cylcase and the inhibition of a cAMP signal transduction pathway. Melatonin not only inhibits adenylate cyclase, but it also activates phosphilpase C. This potentiates the release of arachidonate. By binding to melatonin receptors 1 and 2, the downstream signallling cascades have various effects in the body. The melatonin receptors are G protein-coupled receptors and are expressed in various tissues of the body. There are two subtypes of the receptor in humans, melatonin receptor 1 (MT1) and melatonin receptor 2 (MT2). Melatonin and melatonin receptor agonists, on market or in clinical trials, all bind to and activate both receptor types.The binding of the agonists to the receptors has been investigated for over two decades or since 1986. It is somewhat known, but still not fully understood. When melatonin receptor agonists bind to and activate their receptors it causes numerous physiological processes.
MT1 receptors are expressed in many regions of the central nervous system (CNS): suprachiasmatic nucleus of the hypothalamus (SNC), hippocampus, substantia nigra, cerebellum, central dopaminergic pathways, ventral tegmental area and nucleus accumbens. MT1 is also expressed in the retina, ovary, testis, mammary gland, coronary circulation and aorta, gallbladder, liver, kidney, skin and the immune system. MT2 receptors are expressed mainly in the CNS, also in the lung, cardiac, coronary and aortic tissue, myometrium and granulosa cells, immune cells, duodenum and adipocytes.
The binding of melatonin to melatonin receptors activates a few signaling pathways. MT1 receptor activation inhibits the adenylyl cyclase and its inhibition causes a rippling effect of non activation; starting with decreasing formation of cyclic adenosine monophosphate (cAMP), and then progressing to less protein kinase A (PKA) activity, which in turn hinders the phosphorilation of cAMP responsive element-binding protein (CREB binding protein) into P-CREB. MT1 receptors also activate phospholipase C (PLC), affect ion channels and regulate ion flux inside the cell. The binding of melatonin to MT2 receptors inhibits adenylyl cyclase which decreases the formation of cAMP.[4] As well it hinders guanylyl cyclase and therefore the forming of cyclic guanosine monophosphate (cGMP). Binding to MT2 receptors probably affects PLC which increases protein kinase C (PKC) activity. Activation of the receptor can lead to ion flux inside the cell.</td></tr><tr><th>Absorption</th><td>The absorption and bioavailability of melatonin varies widely.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>n/a</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatically metabolized to at least 14 identified metabolites (identified in mouse urine): 6-hydroxymelatonin glucuronide, 6-hydroxymelatonin sulfate, N-acetylserotonin glucuronide, N-acetylserotonin sulfate, 6-hydroxymelatonin, 2-oxomelatonin, 3-hydroxymelatonin, melatonin glucuronide, cyclic melatonin, cyclic N-acetylserotonin glucuronide, cyclic 6-hydroxymelatonin, 5-hydroxyindole-3-acetaldehyde, di-hydroxymelatonin and its glucuronide conjugate. 6-Hydroxymelatonin glucuronide is the major metabolite found in mouse urine (65-88% of total melatonin metabolites in urine). </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Melatonin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002433" target="_blank">Cytochrome P450 1A2</a></li>
<li><a href="/biodb/bio_entities/BE0003543" target="_blank">Cytochrome P450 1A1</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li></ul></td><td><a href="/metabolites/DBMET00258">6-Hydroxymelatonin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/259">Details</a></td></tr><tr><td>Melatonin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li>
<li><a href="/biodb/bio_entities/BE0002433" target="_blank">Cytochrome P450 1A2</a></li></ul></td><td><a href="/metabolites/DBMET00411"><i>N</i>-Acetyl-5-hydroxytryptamine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/414">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00258">6-Hydroxymelatonin</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00763">6-Hydroxymelatonin sulfate</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1544">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00411"><i>N</i>-Acetyl-5-hydroxytryptamine</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00926"><i>N</i>-Acetyl-5-hydroxytryptamine sulfate</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1545">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00411"><i>N</i>-Acetyl-5-hydroxytryptamine</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0004859" target="_blank">UDP-glucuronosyltransferase</a></li></ul></td><td><a href="/metabolites/DBMET00925"><i>N</i>-Acetyl-5-hydroxytryptamine glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1546">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00258">6-Hydroxymelatonin</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0004859" target="_blank">UDP-glucuronosyltransferase</a></li></ul></td><td><a href="/metabolites/DBMET00762">6-Hydroxymelatonin glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1547">Details</a></td></tr><tr><td>Melatonin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01359">5-Methoxytryptamine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1548">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01359">5-Methoxytryptamine</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01360">Pinoline</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1550">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01359">5-Methoxytryptamine</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01361">Bufotenine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1551">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01361">Bufotenine</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01362"><i>N,N</i>-Dimethyltryptamine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1552">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>35 to 50 minutes</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td><p>Generally well-tolerated when taken orally. The most common side effects, day-time drowsiness, headache and dizziness, appear to occur at the same frequency as with placebo. Other reported side effects include transient depressive symptoms, mild tremor, mild anxiety, abdominal cramps, irritability, reduced alertness, confusion, nausea, vomiting, and hypotension. Safety in Adults: Evidence indicates that it is likely safe to use in oral and parenteral forms for up to two months when used appropriately. Some evidence indicates that it can be safely used orally for up to 9 months in some patients. It is also likely safe to use topically when used appropriately. Safety in Children: Melatonin appeared to be used safely in small numbers of children enrolled in short-term clinical trials. However, concerns regarding safety in children have arisen based on their developmental state. Compared to adults over 20 years of age, people under 20 produce high levels of melatonin. Melatonin levels are inversely related to gonadal development and it is thought that exogenous administration of melatonin may adversely affect gonadal development. Safety during Pregnancy: High doses of melatonin administered orally or parenterally may inhibit ovulation. Not advised for use in individuals who are pregnant or trying to become pregnant. Safety during Lactation: Not recommended as safety has not be established.</p>
<p>Oral, rat: LD<sub>50</sub> &#8805;3200 mg/kg</p>
</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th><th>SMPDB ID</th></tr></thead><tbody><tr><td>Tryptophan Metabolism</td><td>Metabolic</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00063?highlight%5Bcompounds%5D%5B%5D=DB01065&amp;highlight%5Bproteins%5D%5B%5D=DB01065">SMP00063</a></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9928</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5536</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6188</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9569</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6838</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.542</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8231</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.5062</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6505</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.9304</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.8084</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7194</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.6803</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9132
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9498
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.8764
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.8922 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9631
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.5124
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><ul><li>Mason Distributors</li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.nationalvitamin.com">National Vitamin Company</a></li>
<li><a href="http://www.physiologics.com">Physiologics</a></li>
<li><a href="http://www.rugbylaboratories.com">Rugby Laboratories</a></li></ul></td></tr><tr><th>Dosage forms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Melatonin powder</td><td>45.6USD</td><td>g</td></tr><tr><td>Melatonin 3 mg tablet</td><td>0.22USD</td><td>tablet</td></tr><tr><td>Melatonin 5 mg tablet</td><td>0.12USD</td><td>tablet</td></tr><tr><td>Melatonin 5 mg tablet sl</td><td>0.1USD</td><td>tablet</td></tr><tr><td>Melatonin sublingual tablet</td><td>0.09USD</td><td>tablet</td></tr><tr><td>Melatonin 1 mg tablet</td><td>0.03USD</td><td>tablet</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>117 &#176;C</td><td>PhysProp</td></tr><tr><td>logP</td><td>1.6</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>1.43e-01 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>1.42</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>1.15</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-3.2</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>15.8</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (strongest basic)</td><td>-0.94</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>54.12</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>4</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>66.28</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>25.65</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><ul><li><a data-no-turbolink="true" href="/spectra/spectra/nmr_one_d/1693">1H NMR Spectrum</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/1547">MS/MS Spectrum Quattro_QQQ 10</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/1548">MS/MS Spectrum Quattro_QQQ 25</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/1549">MS/MS Spectrum Quattro_QQQ 40</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5222">MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 20</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5223">MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 30</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5224">MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 40</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5225">MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 50</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5226">MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 10</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5227">MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 10</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5228">MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 20</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5229">MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 30</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5230">MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 40</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5231">MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 50</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5232">MS/MS Spectrum LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) </a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5233">MS/MS Spectrum LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) </a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/nmr_two_d/1634">[1H,13C] 2D NMR Spectrum</a></li></ul></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Robert A. S. Welch, Keith Betteridge, &#8220;Method of stimulating cashmere growth on cashmere-producing goats using melatonin.&#8221; U.S. Patent US4855313, issued August, 1986.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=4855313&amp;tbm=pts" target="_blank">US4855313 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Boutin JA, Audinot V, Ferry G, Delagrange P: Molecular tools to study melatonin pathways and actions. Trends Pharmacol Sci. 2005 Aug;26(8):412-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15992934">Pubmed</a></li>
	<li>Caniato R, Filippini R, Piovan A, Puricelli L, Borsarini A, Cappelletti EM: Melatonin in plants. Adv Exp Med Biol. 2003;527:593-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15206778">Pubmed</a></li>
	<li>Hardeland R: Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine. 2005 Jul;27(2):119-30. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16217125">Pubmed</a></li>
	<li>Hattori A, Migitaka H, Iigo M, Itoh M, Yamamoto K, Ohtani-Kaneko R, Hara M, Suzuki T, Reiter RJ: Identification of melatonin in plants and its effects on plasma melatonin levels and binding to melatonin receptors in vertebrates. Biochem Mol Biol Int. 1995 Mar;35(3):627-34. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7773197">Pubmed</a></li>
	<li>Ma X, Chen C, Krausz KW, Idle JR, Gonzalez FJ: A metabolomic perspective of melatonin metabolism in the mouse. Endocrinology. 2008 Apr;149(4):1869-79. Epub 2008 Jan 10. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18187545">Pubmed</a></li>
	<li>Reiter RJ, Acuna-Castroviejo D, Tan DX, Burkhardt S: Free radical-mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system. Ann N Y Acad Sci. 2001 Jun;939:200-15. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11462772">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C01598" target="_blank">C01598 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=896" target="_blank">896 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46509101" target="_blank">46509101 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.872.html" target="_blank">872 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>BindingDB</td><td><a class="wishart-link-out" href="http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=9019" target="_blank">9019 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=16796" target="_blank">16796 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL45" target="_blank">CHEMBL45 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000429" target="_blank">DAP000429 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA164752558" target="_blank">PA164752558 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>IUPHAR</td><td><a class="wishart-link-out" href="http://www.iuphar-db.org/DATABASE/LigandDisplayForward?ligandId=1357" target="_blank">1357 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Guide to Pharmacology</td><td><a class="wishart-link-out" href="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1357" target="_blank">1357 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>HET</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/msd-srv/chempdb/cgi-bin/cgi.pl?FUNCTION=getByCode&amp;CODE=ML1" target="_blank">ML1 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=793167" target="_blank">793167 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/melatonin.html" target="_blank">http://www.drugs.com/melatonin.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PDRhealth</td><td><a class="wishart-link-out" href="http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/mel_0286.shtml" target="_blank">http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/mel_0286.shtml <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Melatonin" target="_blank">Melatonin <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>N05CH01<ul class="atc-drug-tree"><li><a href="/atc/N#N">N &#8212; NERVOUS SYSTEM</a></li><li><a href="/atc/N05#N05">N05 &#8212; PSYCHOLEPTICS</a></li><li><a href="/atc/N05C#N05C">N05C &#8212; HYPNOTICS AND SEDATIVES</a></li><li><a href="/atc/N05CH#N05CH">N05CH &#8212; Melatonin receptor agonists</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB01065.pdf?1265922741">show</a>(72 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01115">Nifedipine</a></td><td>Melatonin can possibly decrease the effect of nifedipine</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>